Payment overview · 2025
General Payments
$206.36
10 reported records · 7 companies
Healthcare provider profile · identity verified
John Robert Ameen, DO
Allopathic & Osteopathic Physicians|Internal Medicine · SPRING HILL, FL · NPI 1316435688
Verified facts
What the public records show
CMS Open Payments records show John Robert Ameen, DO received $206.36 in general payments during 2025 across 10 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.21 | 23.4% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.15 | 22.4% | 2 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $24.60 | 11.9% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $24.36 | 11.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.92 | 11.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.02 | 9.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.10 | 9.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $206.36 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $48.21 | 3 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $46.15 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.92 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
82 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 371 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 99 |
| Losartan Potassium | Losartan Potassium | 274 | 88 |
| Lisinopril | Lisinopril | 268 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 257 | 82 |
| Metformin Hcl | Metformin Hcl | 249 | 72 |
| Simvastatin | Simvastatin | 241 | 66 |
| Omeprazole | Omeprazole | 209 | 76 |
| Meloxicam | Meloxicam | 203 | 83 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 202 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 200 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 192 | 58 |
| Gabapentin | Gabapentin | 189 | 61 |
| Furosemide | Furosemide | 182 | 57 |
| Alprazolam | Alprazolam | 181 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 168 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 49 |
| Glimepiride | Glimepiride | 141 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 132 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 35 |
| Tramadol Hcl | Tramadol Hcl | 102 | 27 |
| Trazodone Hcl | Trazodone Hcl | 101 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 94 | 23 |
| Atenolol | Atenolol | 93 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 89 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 29 |
| Buspirone Hcl | Buspirone Hcl | 84 | 23 |
| Eliquis | Apixaban | 82 | 28 |
| Carvedilol | Carvedilol | 80 | 26 |
| Montelukast Sodium | Montelukast Sodium | 79 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 15 |
| Potassium Chloride | Potassium Chloride | 67 | 17 |
| Sildenafil Citrate | Sildenafil Citrate | 66 | 16 |
| Ibuprofen | Ibuprofen | 62 | 24 |
| Sertraline Hcl | Sertraline Hcl | 62 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | 21 |
| Finasteride | Finasteride | 58 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 16 |
| Lorazepam | Lorazepam | 55 | 16 |
| Glipizide | Glipizide | 50 | 14 |
| Jardiance | Empagliflozin | 50 | 11 |
| Clonazepam | Clonazepam | 49 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 45 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | 18 |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Temazepam | Temazepam | 42 | 11 |
| Enalapril Maleate | Enalapril Maleate | 41 | suppressed |
| Spironolactone | Spironolactone | 40 | 15 |
| Celecoxib | Celecoxib | 39 | 17 |
| Famotidine | Famotidine | 36 | 17 |
| Ozempic | Semaglutide | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 15 |
| Pregabalin | Pregabalin | 32 | 14 |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Prednisone | Prednisone | 31 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 22 |
| Azithromycin | Azithromycin | 28 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | 11 |
| Acyclovir | Acyclovir | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Topiramate | Topiramate | 23 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 11 |
| Ramipril | Ramipril | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 15 |
| Folic Acid | Folic Acid | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Oxazepam | Oxazepam | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $206.36 · 10 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, BREZTRI, CAPVAXIVE, COMIRNATY, Flexitouch Plus, KEVEYIS, Nimbl, PREVNAR 20, TRELEGY ELLIPTA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error